Answers are grounded in this paper and cite their sources.
Sacubitril/valsartan (S/V) is used in managing heart failure with reduced ejection fraction (HFrEF), reducing morbidity and mortality while improving symptoms and prognosis. This study aims to evaluate the effectiveness of S/V in patients with reduced left ventricular ejection fraction (LVEF) and its safety.
No takes yet. Share an insight, caveat, or question.
Raddadi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: